Millendo Therapeutics Inc (NASDAQ:MLND) – Stock analysts at Jefferies Financial Group dropped their Q1 2019 earnings estimates for shares of Millendo Therapeutics in a research note issued on Monday, April 1st, according to Zacks Investment Research. Jefferies Financial Group analyst D. Hoang now expects that the company will post earnings of ($0.59) per share for the quarter, down from their prior forecast of ($0.56). Jefferies Financial Group has a “Buy” rating and a $22.00 price objective on the stock. Jefferies Financial Group also issued estimates for Millendo Therapeutics’ Q2 2019 earnings at ($0.64) EPS, Q3 2019 earnings at ($0.72) EPS, Q4 2019 earnings at ($0.80) EPS, FY2019 earnings at ($2.75) EPS, FY2020 earnings at ($2.31) EPS and FY2021 earnings at ($2.82) EPS.
Other analysts also recently issued reports about the company. LADENBURG THALM/SH SH started coverage on Millendo Therapeutics in a research note on Friday, January 4th. They issued a “buy” rating and a $29.00 target price for the company. ValuEngine upgraded Millendo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research upgraded Millendo Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Thursday, April 4th. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $23.25.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Frazier Management LLC bought a new stake in shares of Millendo Therapeutics in the 4th quarter worth approximately $11,103,000. Great Point Partners LLC purchased a new stake in Millendo Therapeutics during the fourth quarter valued at about $10,240,000. Adams Street Partners LLC purchased a new stake in Millendo Therapeutics during the fourth quarter valued at about $3,285,000. Prosight Management LP purchased a new stake in Millendo Therapeutics during the fourth quarter valued at about $2,041,000. Finally, Worth Venture Partners LLC purchased a new stake in Millendo Therapeutics during the fourth quarter valued at about $206,000. Hedge funds and other institutional investors own 42.52% of the company’s stock.
About Millendo Therapeutics
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Read More: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.